浅谈医学科研论文文后参考文献的著录

准确规范的文献标引有助于提高医学科研论文查全率、查准率,便于文献的统计和对期刊的正确评价。为帮助医学科研论文作者方便快捷地解决此问题,就医学论文文后参考文献的正确标引做一简述。     

Effect of Trastuzumab on Health-Related Quality of Life in Patients With HER2-Positive Metastatic Breast Cancer: Data From Three Clinical Trials

BackgroundTrastuzumab (Herceptin®; Genentech, Inc.; South San Francisco, CA) provides clinical benefit when combined with chemotherapy or as monotherapy in patients with HER2-positive metastatic breast cancer (MBC). Given the demonstrated improvement in standard outcomes, it is important to assess this therapy—s effect on patients' health-related quality of life (HRQOL).Patients and MethodsThe QLQ-C30 and BR-23 questionnaires were used to assess global HRQOL; physical, social, and role functioning; and fatigue as secondary endpoints in trials of trastuzumab monotherapy (H0649g and H0650g) or in combination with chemotherapy (H0648g). Patients completed assessments at baseline, week 8 (H0648g only), and at 12-week intervals until disease progression.ResultsIn H0648g (n = 400), more patients exhibited improved global QOL in the chemotherapy-plus-trastuzumab versus chemotherapy arms (51% vs. 36%; P < .05). In the chemotherapy-plus-trastuzumab arm, fatigue was significantly improved at week 32 (chemotherapy completed at week 20) compared with baseline in both study arms (P < .05); more patients in the chemotherapy-plus-trastuzumab arm also showed improved physical and role functioning. Subscale scores in H0649g (n = 154) and H0650g (n = 74) were similar at all time points. In H0649g, clinical responders showed meaningful improvements (≥ 10 points) in all 5 subscales by week 12 through week 36. Nonresponders had meaningful decreases in all subscale scores. In H0650g, clinical responders exhibited meaningful increases in social and role functioning and global QOL by week 12; nonresponder scores worsened for all subscales.ConclusionTrastuzumab has a beneficial effect on HRQOL in patients with HER2-positive MBC, particularly those with responsive disease.     

Association of serum levels of lipid and its novel constituents with the different stages of esophageal carcinoma

Background  

The aim of the study was to evaluate the association of immunoglobulin G type of autoantibodies to oxidized low-density lipoprotein (oxLDL-lgG) and oxLDL-lgM with the progression of esophageal squamous cell carcinoma (ESSC).     

Prognostic value of expression of EGFR and nm23 for locoregionally advanced nasopharyngeal carcinoma

The purpose of this study was to evaluate the prognostic value of expression of EGFR and nm23 in patients with advanced-stage nasopharyngeal carcinoma (NPC). The study population comprised 127 patients with stage III–IVa NPC with sufficient pretreatment tumor biopsy specimens from 2003 to 2004 and clinical follow-up data. The expression of EGFR and nm23 was detected by immunohistochemistry. Survival analysis was performed using Kaplan–Meier method. The correlation between pretreatment expression of EGFR and nm23, and the effectiveness of chemoradiotherapy was analyzed. The EGFR expression was correlated with primary lesion stage and clinical stage (P = 0.001, 0.002, respectively). There was a statistically significant association between nm23 expression and local lymph node stage (P = 0.000). The positive EGFR expression had a higher recurrent rate than the negative (P = 0.015). The positive nm23 expression had a lower distant metastasis rate than the negative (P = 0.021). Negative expression of EGFR had a significantly better 5-year OS and DFS than positive expression (P = 0.015, 0.013, respectively). Positive expression of nm23 had a significantly higher 5-year OS and DFS than negative expression (P = 0.001, 0.006, respectively). Multivariate analysis indicated that both pretreatment EGFR and nm23 expression were strong independent factors for the overall survival of patients with NPC (P = 0.000, 0.000, respectively). Our data suggested that EGFR and nm23 can serve as reliable biomarkers for prognosis prediction in patients with NPC who may benefit from alternate treatment strategy and targeted treatment.     

宫清颗粒诱导Th17/Treg亚群偏移减轻药物流产后子宫出血

目的探讨米非司酮药物流产中Th17/Treg亚群偏移与子宫出血量的相关性及宫清颗粒诱导Th17/Treg亚群偏移减轻药物流产后子宫出血的作用与机制。方法孕小鼠30只,随机分为正常妊娠组和米非司酮大(1.5 mg·kg~(-1)·d~(-1)×3 d,ig)、小剂量组(0.88 mg·kg~(-1)·d~(-1)×3 d,ig),每组10只,改良碱性正铁血红素法检测子宫出血量,流式细胞术双染色法检测子宫组织Th17(CD3~+CD4~+IL-17A~+)、Treg(CD4~+CD25~+Foxp3~+)亚群比例。孕小鼠40只,随机分为米非司酮组(1.5 mg·kg~(-1)·d~(-1)×3 d,ig)和宫清大、中、小剂量组(米非司酮1.5 mg·kg~(-1)·d~(-1)×3 d+宫清颗粒308.16、154.08、77.04 mg·kg~(-1)·d~(-1)×5 d,ig),每组10只,检测子宫出血量及子宫组织Th17、Treg亚群比例,RT-PCR法检测子宫组织白细胞介素-17A(IL-17A)、白细胞介素-10(IL-10)、转化生长因子-β(TGF-β)mRNA转录水平。结果药物流产小鼠子宫出血量与Th17亚群比例、Th17/Treg比值呈负相关(r=-0.700、r=-0.867,P<0.05),与Treg亚群比例呈正相关(r=0.554,P<0.05)。宫清颗粒作用后小鼠子宫出血量明显减少;Th17亚群比例升高,Treg亚群比例降低,Th17/Treg比值升高(均P<0.05);IL-17A mRNA表达升高,IL-10、TGF-βmRNA表达降低,均P<0.05。结论米非司酮药物流产中Th17/Treg亚群偏移与子宫出血量密切相关,宫清颗粒优势诱导Th17亚群偏移,进而减轻子宫出血。